Long-term pharmacological management of phenylketonuria, including patients below the age of 4 years.

about

Elevated levels of plasma phenylalanine in schizophrenia: a guanosine triphosphate cyclohydrolase-1 metabolic pathway abnormality?The complete European guidelines on phenylketonuria: diagnosis and treatment.

P2860

Q37500605-BCC2825F-5951-4F5A-878C-3ED9EA68681B Q42376686-368DBCC4-9A2F-4EEE-A4E1-0759FA3E2566

P2860

Long-term pharmacological management of phenylketonuria, including patients below the age of 4 years.

Item

http://www.wikidata.org/entity/Q42367760

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Long-term pharmacological mana ...... ents below the age of 4 years.

@en

Long-term pharmacological mana ...... ents below the age of 4 years.

@nl

type

Item

label

Long-term pharmacological mana ...... ents below the age of 4 years.

@en

Long-term pharmacological mana ...... ents below the age of 4 years.

@nl

prefLabel

Long-term pharmacological mana ...... ents below the age of 4 years.

@en

Long-term pharmacological mana ...... ents below the age of 4 years.

@nl

P1476

Long-term pharmacological mana ...... ients below the age of 4 years

@en

P2093

A Pérez-Muñuzuri

http://www.w3.org/2001/XMLSchema#string

E Valerio

http://www.w3.org/2001/XMLSchema#string

M D Bóveda

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study.

Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria.

Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria.

Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria.

Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo.

Tetrahydrobiopterin responsiveness after extended loading test of 12 Danish PKU patients with the Y414C mutation.

Management of phenylketonuria in Europe: survey results from 19 countries.

Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency in Dutch neonates.

Long-term follow-up of patients with phenylketonuria receiving tetrahydrobiopterin treatment.

Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene.

P304

91-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/8904_2011_53

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

José M Fraga

María L Couce

P577

2011-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235691414

http://www.w3.org/2001/XMLSchema#string

P698

23430859

http://www.w3.org/2001/XMLSchema#string

P921

phenylketonuria

P932

3509844

http://www.w3.org/2001/XMLSchema#string

Long-term pharmacological management of phenylketonuria, including patients below the age of 4 years.

about

P2860

P2860

Long-term pharmacological management of phenylketonuria, including patients below the age of 4 years.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P921

P932